Conagra Brands Inc vs Johnson & Johnson — how do they compare? Conagra Brands Inc trades at $15.02 (market cap $7.14B), while Johnson & Johnson trades at $260.79 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 87.7× Conagra Brands Inc's market cap, and Conagra Brands Inc pays the higher dividend (8.2%). Which is the better fit depends on your goals.
| CAG | JNJ | |
|---|---|---|
Market Cap | $7.14B | $626.09B |
Sector | Consumer Staples | Health |
52-Week High | $20.02 | $267.24 |
52-Week Low | $12.58 | $172.78 |
Enterprise Value | $14.20B | $654.37B |
Dividend Yield | 8.2% | 2.06% |
Volume | — | 6,156,228 |
Signals from Pluang's Aura AI — not financial advice
Conagra Brands (CAG) trades at $14.985, up 1.39% with neutral technical signals. The company shows mixed fundamentals with a P/E of 10.06 and P/S of 0.63 suggesting undervaluation, but negative net income margin (-16.99%) and ROE (-25.06%) reflect profitability challenges. Recent earnings show two beats and one miss in the last four quarters, with Q3 2026 results pending. The company recently cut its dividend by 50% to prioritize debt reduction and operational improvements under new CEO John Brase.
CAG presents a turnaround story with attractive valuation metrics but faces significant headwinds including declining sales, margin pressure, and high debt levels. Analyst consensus is cautious with 62.5% hold ratings and a $13.67 price target below current levels. The dividend cut provides financial flexibility but signals ongoing challenges. Investors should weigh the discounted valuation against persistent operational pressures and weak growth outlook.
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Trailing returns across standard periods
Latest headlines on both assets
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →